EUROAPI, a leading provider of small molecule APIs and listed on Euronext Paris, has acquired 100% of the shares in BianoGMP GmbH (“BianoGMP”).
BianoGMP, based in Gera (Thuringia), was founded in 2017 by Prof. Dr. Tobias Pöhlmann and Dr. Rolf Günther and is an oligonucleotide Contract Development and Manufacturing Organization (CDMO) player focused on small-scale, early-stage (pre-clinical to phase 1), complex and customized projects, with a diversified client base in Europe and Asia.
With this acquisition, EUROAPI aims to further strengthen its CDMO market position in the oligonucleotides sector. This transaction not only opens up opportunities for cross-referral commercial synergies and scientific cooperation, but will also further differentiate the value proposition of EUROAPI to accompany a wider client base across the whole oligonucleotide development continuum, from research to commercialization.
Consistent with EUROAPI’s entrepreneurial approach, BianoGMP will retain its corporate brand and become a EUROAPI company.
“I am thrilled to have the opportunity to continue to expand BianoGMP’s capabilities in order to grow with our customers and provide GMP-batches also for later clinical phases,” said Prof. Dr. Tobias Pöhlmann. “BianoGMP has a track record of hands-on support for innovative oligonucleotide developments, complex chemistries and conjugation of peptides and lipids. With a client base in Europe and Asia, it will benefit from EUROAPI’s sales and marketing teams to expand into new geographies.”
“We at bm|t are proud to have supported and accompanied BianoGMP in the process of setting up a GMP production from the very beginning, together with a number of co-investors,” said Stefan Jahn, Senior Investment Manager at bm|t. “We are delighted that BianoGMP has found a strategic partner and new owner in EUROAPI, who also wants to invest in the Gera location and expand BianoGMP’s production capacities”.
More information about EUROAPI
More information about BianoGMP
More information about bm|t